Are you a Health Professional? Jump over to the doctors only platform. Click Here

Drug originally intended for diabetes may help Alzheimer’s patients

Senior Woman In Discussion With Health Visitor At Home
Print Friendly, PDF & Email

A researcher with the Faculty of Medicine & Dentistry at the University of Alberta has discovered that a drug originally intended for diabetes may hold promise in the fight against Alzheimer’s disease.

Dr Jack Jhamandas, of the faculty’s Division of Neurology, and his research team are excited about the potential that drug AC253 could have for Alzheimer’s patients. The drug was developed to treat diabetes but never made it to market.

During tests in his lab, Jhamandas and his team discovered that this drug blocked the toxic effects of a protein that is deposited in large quantities in the brains of Alzheimer’s patients. This beta amyloid protein, which is linked to the cause of Alzheimer’s, makes brain cells toxic – ultimately causing the brain cells to die.

“From the point of view of therapies, it may open up some new avenues for us to explore in terms of treatment for Alzheimer’s disease,” says Jhamandas. “I think patients with this condition, their families and caregivers, live on a word called hope and this is a type of a discovery that engenders that hope, that ignites that hope and that keeps it burning.”

Jhamandas and his research team, who are funded by the Canadian Institutes of Health Research (CIHR), published their results in the peer-reviewed American Journal of Pathology in January.

The team reported two other significant discoveries related to Alzheimer’s. They found a second way to block the toxic effects of beta amyloid protein, using a relatively new technique to “silence” a gene involved in the process of brain cell death. By silencing the gene, numerous processes triggering cell death were blocked, so they were able to prevent brain cells from dying.

“We altered the genes and low and behold, beta amyloid protein lost its ability to kill brain cells as effectively as it normally would,” says Jhamandas.


The third finding, this one in collaboration with David Westaway, a fellow Alzheimer’s researcher in the faculty, relates to basic understanding of the disease. They discovered these genes weren’t everywhere in the brain. Both these genes and the toxic protein were only found in large quantities in areas of the brain responsible for memory, learning and cognition, says Jhamandas.

“It was quite a surprising observation. We’re not sure what it fully means, so we are in the process of looking at this in brain tissue from Alzheimer’s patients.”

Jhamandas said some of the next steps for his research team are to inject a compound into the brains of lab models to see if learning and memory problems can be stopped or prevented. If that is the case, it “really could be the launching point for a development of compounds that could be tried in human clinical trials.”

(Source: University of AlbertaAmerican Journal of Pathology)


Print Friendly, PDF & Email

Dates

Posted On: 7 February, 2011
Modified On: 15 January, 2014

Tags



Created by: myVMC